Masimo’s (MASI) “Buy” Rating Reaffirmed at Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of Masimo (NASDAQ:MASI) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $190.00 target price on the medical equipment provider’s stock, up from their previous target price of $170.00.

Several other equities analysts have also issued reports on MASI. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. BTIG Research increased their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their price objective on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company increased their target price on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Stock Up 2.7 %

Shares of Masimo stock opened at $177.70 on Friday. Masimo has a 1 year low of $91.60 and a 1 year high of $178.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a 50-day moving average of $143.48 and a 200 day moving average of $128.00. The firm has a market cap of $9.51 billion, a price-to-earnings ratio of 121.62 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the firm posted $0.63 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Masimo will post 4.04 earnings per share for the current fiscal year.

Institutional Trading of Masimo

A number of hedge funds have recently bought and sold shares of MASI. NBC Securities Inc. grew its stake in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the period. HHM Wealth Advisors LLC increased its holdings in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in Masimo by 5,730.0% in the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 573 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.